104 related articles for article (PubMed ID: 17786040)
1. mDia function is critical for the cell suicide program triggered by farnesyl transferase inhibition.
Kamasani U; Duhadaway JB; Alberts AS; Prendergast GC
Cancer Biol Ther; 2007 Sep; 6(9):1422-7. PubMed ID: 17786040
[TBL] [Abstract][Full Text] [Related]
2. Cyclin B1 is a critical target of RhoB in the cell suicide program triggered by farnesyl transferase inhibition.
Kamasani U; Huang M; Duhadaway JB; Prochownik EV; Donover PS; Prendergast GC
Cancer Res; 2004 Nov; 64(22):8389-96. PubMed ID: 15548709
[TBL] [Abstract][Full Text] [Related]
3. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
DuHadaway JB; Du W; Donover S; Baker J; Liu AX; Sharp DM; Muller AJ; Prendergast GC
Oncogene; 2003 Jun; 22(23):3578-88. PubMed ID: 12789266
[TBL] [Abstract][Full Text] [Related]
4. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.
Du W; Lebowitz PF; Prendergast GC
Mol Cell Biol; 1999 Mar; 19(3):1831-40. PubMed ID: 10022870
[TBL] [Abstract][Full Text] [Related]
5. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors.
Liu Ax; Du W; Liu JP; Jessell TM; Prendergast GC
Mol Cell Biol; 2000 Aug; 20(16):6105-13. PubMed ID: 10913192
[TBL] [Abstract][Full Text] [Related]
6. Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors.
Zeng PY; Rane N; Du W; Chintapalli J; Prendergast GC
Oncogene; 2003 Feb; 22(8):1124-34. PubMed ID: 12606940
[TBL] [Abstract][Full Text] [Related]
7. Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor.
van Golen KL; Bao L; DiVito MM; Wu Z; Prendergast GC; Merajver SD
Mol Cancer Ther; 2002 Jun; 1(8):575-83. PubMed ID: 12479217
[TBL] [Abstract][Full Text] [Related]
8. Genetic response to farnesyltransferase inhibitors: proapoptotic targets of RhoB.
Kamasani U; Liu AX; Prendergast GC
Cancer Biol Ther; 2003; 2(3):273-80. PubMed ID: 12878865
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
10. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors.
Du W; Prendergast GC
Cancer Res; 1999 Nov; 59(21):5492-6. PubMed ID: 10554025
[TBL] [Abstract][Full Text] [Related]
11. Activation of the RhoB signaling pathway by thyroid hormone receptor β in thyroid cancer cells.
Ichijo S; Furuya F; Shimura H; Hayashi Y; Takahashi K; Ohta K; Kobayashi T; Kitamura K
PLoS One; 2014; 9(12):e116252. PubMed ID: 25548921
[TBL] [Abstract][Full Text] [Related]
12. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
13. The farnesyltransferase inhibitor, LB42708, inhibits growth and induces apoptosis irreversibly in H-ras and K-ras-transformed rat intestinal epithelial cells.
Kim HS; Kim JW; Gang J; Wen J; Koh SS; Koh JS; Chung HH; Song SY
Toxicol Appl Pharmacol; 2006 Sep; 215(3):317-29. PubMed ID: 16712893
[TBL] [Abstract][Full Text] [Related]
14. Geranylgeranylated RhoB is sufficient to mediate tissue-specific suppression of Akt kinase activity by farnesyltransferase inhibitors.
Liu A; Prendergast GC
FEBS Lett; 2000 Sep; 481(3):205-8. PubMed ID: 11007964
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras.
Brassard DL; English JM; Malkowski M; Kirschmeier P; Nagabhushan TL; Bishop WR
Exp Cell Res; 2002 Feb; 273(2):138-46. PubMed ID: 11822869
[TBL] [Abstract][Full Text] [Related]
16. Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression.
Zhang B; Prendergast GC; Fenton RG
Cancer Res; 2002 Jan; 62(2):450-8. PubMed ID: 11809695
[TBL] [Abstract][Full Text] [Related]
17. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.
Lebowitz PF; Prendergast GC
Oncogene; 1998 Sep; 17(11 Reviews):1439-45. PubMed ID: 9779989
[TBL] [Abstract][Full Text] [Related]
18. Farnesyltransferase inhibitors define a role for RhoB in controlling neoplastic pathophysiology.
Prendergast GC
Histol Histopathol; 2001 Jan; 16(1):269-75. PubMed ID: 11193202
[TBL] [Abstract][Full Text] [Related]
19. Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells.
Pan J; She M; Xu ZX; Sun L; Yeung SC
Cancer Res; 2005 May; 65(9):3671-81. PubMed ID: 15867362
[TBL] [Abstract][Full Text] [Related]
20. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment.
Lebowitz PF; Sakamuro D; Prendergast GC
Cancer Res; 1997 Feb; 57(4):708-13. PubMed ID: 9044849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
